Related Experiment Videos
Clindamycin-associated acute generalized exanthematous pustulosis
C Croy1, K Buehrle2, J Austin Szwak3
1Department of Pharmacy, Medical University of South Carolina Medical Center, Charleston, SC, USA.
Journal of Clinical Pharmacy and Therapeutics
|April 19, 2017
Summary
Acute generalized exanthematous pustulosis (AGEP) is a severe skin reaction often linked to medications. This case highlights clindamycin as a potential cause of AGEP, emphasizing early identification for prompt treatment.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Acute generalized exanthematous pustulosis (AGEP) is a rare but severe cutaneous drug reaction.
- Clindamycin is infrequently associated with dermatologic adverse events.
Observation:
- A patient developed AGEP while being treated with vancomycin and clindamycin.
- The patient's rash significantly improved after clindamycin was discontinued.
Findings:
- This case suggests clindamycin can be a causative agent in AGEP.
- Early identification of the offending antibiotic is crucial for managing adverse skin reactions.
Implications:
- Clinicians should consider clindamycin as a potential cause of AGEP.
- Prompt recognition and withdrawal of the causative agent can lead to rapid improvement of AGEP symptoms.
- Timely management of antibiotic-induced skin reactions is essential for patient outcomes.